The jump wasn't driven by a few high-profile drug problems, such as Merck's withdrawal of painkiller Vioxx in 2004 and Pfizer's suspension of rival painkiller Bextra in 2005.
One of those drugs was the anti-inflammatory medication Bextra, which Pfizer pulled off the market in 2005 after it was linked to increasing the risk of heart attacks and strokes.